[Form 4] PROVECTUS BIOPHARMACEUTICALS, INC. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
9,436 shares exercised/converted
Mixed
2 txns
Insider
Pershing Edward
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | 8% Unsecured Convertible Promissory Note | 0 | $0.00 | -- |
| Exercise | Series D-1 Convertible Preferred Stock | 9,436 | $0.00 | -- |
Holdings After Transaction:
8% Unsecured Convertible Promissory Note — 0 shares (Direct, null);
Series D-1 Convertible Preferred Stock — 2,857,285 shares (Direct, null)
Footnotes (1)
- Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On June 05, 2026, the 2025 Note was converted into 9,436 shares of Series D-1 Preferred Stock.
Key Figures
Common shares acquired: 94,360 shares
Preferred shares issued: 9,436 shares
Note conversion price: $2.862 per preferred share
+3 more
6 metrics
Common shares acquired
94,360 shares
Common stock received from converting Series D-1 Preferred on transaction date
Preferred shares issued
9,436 shares
Series D-1 Convertible Preferred Stock from 8% note conversion
Note conversion price
$2.862 per preferred share
Conversion of 8% unsecured convertible promissory note into Series D-1 Preferred
Post-transaction common holdings
2,857,285 shares
Common stock directly owned after derivative exercises and conversions
Preferred-to-common ratio
10 common per 1 preferred
Conversion ratio for Series D-1 Convertible Preferred Stock into common stock
Automatic conversion date
December 31, 2028
Automatic conversion of Series D-1 Preferred into common if not earlier converted
Key Terms
Series D-1 Convertible Preferred Stock, 8% unsecured convertible promissory note, Certificate of Designation, 2025 Financing
4 terms
Series D-1 Convertible Preferred Stock financial
"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"
8% unsecured convertible promissory note financial
"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"
Certificate of Designation regulatory
"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
2025 Financing financial
"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"
FAQ
What did PVCT CEO Edward Pershing report in this Form 4 filing?
Edward Pershing reported exercising convertible securities to acquire more PROVECTUS BIOPHARMACEUTICALS (PVCT) common stock. An 8% unsecured convertible note converted into Series D-1 preferred shares, which then converted into 94,360 common shares, increasing his direct ownership.
What is the conversion ratio of PVCT Series D-1 Convertible Preferred Stock?
Each share of PROVECTUS BIOPHARMACEUTICALS (PVCT) Series D-1 Convertible Preferred Stock is convertible into 10 common shares. In this filing, 9,436 preferred shares were effectively converted, producing 94,360 additional shares of common stock for the reporting person.
What was the conversion price for the PVCT 8% unsecured convertible promissory note?
The 8% unsecured convertible promissory note of PROVECTUS BIOPHARMACEUTICALS (PVCT) converted into Series D-1 preferred stock at $2.862 per preferred share. This automatic conversion created 9,436 preferred shares, which are themselves convertible into common stock at a fixed 10-to-1 ratio.